Close Menu

NEW YORK (GenomeWeb) – Roche said today that it has received the CE mark for its Navify Mutation Profiler clinical software, which it launched today.

The software provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer. Along with it, Roche launched Navify Therapy Matcher, an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.